Abstract
The ability of a single protein fold to make multi-modal interactions with itself and others for transmitting biological signals across multiple receptor families is a recurring theme in signal transduction. The Toll/IL-1 receptor (TIR) domain represents an evolutionarily conserved alpha-beta Flavodoxin-like protein fold [1], which has evolved complex multifaceted molecular interactions capable of transmitting a variety of developmental and immunological signals. In mammals, TIR domains are found on both interleukin-1 receptors (IL-1Rs) and Toll-like receptors (TLRs), as well as in cytoplasmic signaling adaptors and endogenous regulatory proteins. Appropriate TIR-TIR mediated immune interactions result in cytokine responses, pathogen clearance and host immune protection, while inappropriate signaling can lead to autoimmunity, inflammation and death. In the past decade, a number of three-dimensional structures of individual TIR domains have been elucidated. When coupled with the wealth of information from mutagenesis, genetic and peptide studies, this structural data provides additional insight to the molecular mechanisms underlying signal transduction mediated by interactions between TIR domains. Owing to their ability to regulate both innate and adaptive immune responses in a variety of organisms including humans, TIR domain-mediated molecular interactions are of intense interest for therapies targeting autoimmunity, cancer and emerging host-pathogen interactions. Here, we review progress in the development of peptides, peptidomimetics and small molecules designed to regulate TIR-dependent signaling in the context of recent advances in structural and molecular studies of TIR domain proteins and their interactions.
Keywords: Toll-like receptors, TIR domain, Innate Immunity, NF-κB, Interleukin receptors, peptides, peptidomimetics.
Current Pharmaceutical Design
Title:Molecular Interactions in Interleukin and Toll-like Receptor Signaling Pathways
Volume: 20 Issue: 8
Author(s): Greg A. Snyder and Eric J. Sundberg
Affiliation:
Keywords: Toll-like receptors, TIR domain, Innate Immunity, NF-κB, Interleukin receptors, peptides, peptidomimetics.
Abstract: The ability of a single protein fold to make multi-modal interactions with itself and others for transmitting biological signals across multiple receptor families is a recurring theme in signal transduction. The Toll/IL-1 receptor (TIR) domain represents an evolutionarily conserved alpha-beta Flavodoxin-like protein fold [1], which has evolved complex multifaceted molecular interactions capable of transmitting a variety of developmental and immunological signals. In mammals, TIR domains are found on both interleukin-1 receptors (IL-1Rs) and Toll-like receptors (TLRs), as well as in cytoplasmic signaling adaptors and endogenous regulatory proteins. Appropriate TIR-TIR mediated immune interactions result in cytokine responses, pathogen clearance and host immune protection, while inappropriate signaling can lead to autoimmunity, inflammation and death. In the past decade, a number of three-dimensional structures of individual TIR domains have been elucidated. When coupled with the wealth of information from mutagenesis, genetic and peptide studies, this structural data provides additional insight to the molecular mechanisms underlying signal transduction mediated by interactions between TIR domains. Owing to their ability to regulate both innate and adaptive immune responses in a variety of organisms including humans, TIR domain-mediated molecular interactions are of intense interest for therapies targeting autoimmunity, cancer and emerging host-pathogen interactions. Here, we review progress in the development of peptides, peptidomimetics and small molecules designed to regulate TIR-dependent signaling in the context of recent advances in structural and molecular studies of TIR domain proteins and their interactions.
Export Options
About this article
Cite this article as:
Snyder A. Greg and Sundberg J. Eric, Molecular Interactions in Interleukin and Toll-like Receptor Signaling Pathways, Current Pharmaceutical Design 2014; 20 (8) . https://dx.doi.org/10.2174/13816128113199990069
DOI https://dx.doi.org/10.2174/13816128113199990069 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Determination of 7,12-Dimethylbenz[a]Anthracene in Orally Treated Rats by High-Performance Liquid Chromatography and Transfer Stripping Voltammetry
Combinatorial Chemistry & High Throughput Screening Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Current Molecular Medicine Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Retinal Pigment Epithelium Regeneration by Induced Pluripotent Stem Cells; Therapeutic and Modelling Approaches on Retinal Degenerative Diseases
Current Stem Cell Research & Therapy Evaluation of microRNA Stability in Plasma and Serum from Healthy Dogs
MicroRNA <i>In Vivo</i> Anti-Tumor Effects of Flavokawain A in 4T1 Breast Cancer Cell-Challenged Mice
Anti-Cancer Agents in Medicinal Chemistry Comparison of Large Proteomic Datasets
Current Proteomics The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
Cardiovascular & Hematological Agents in Medicinal Chemistry Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Natural and Structure-based RXR Ligand Scaffolds and Their Functions
Current Topics in Medicinal Chemistry Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
Current Drug Targets Development and Application of Fourier-Transform Infrared Chemical Imaging of Tumour in Human Tissue
Current Medicinal Chemistry Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry